Sponsor Pipeline

Shanghai Runshi Pharmaceutical Technology Co., Ltd Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
0
Recruiting
2
Phase 3
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-02 NCT06512428
A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
overall status: Recruiting → Unknown
Active Trials by Phase
Phase 3
2
Phase 2
1
Phase 1/2
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06656091 A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal… Advanced Oesophageal Squamous Cell Carcinoma Not Yet Recruiting
NCT07613450 A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas High Grade Meningioma Not Yet Recruiting
Phase 2
NCT06739213 A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma Recurrent or Progressive High Grade Meningioma Not Yet Recruiting
Phase 1/2
NCT06132217 A Study of Simmitinib Plus SG001 in Advanced Solid Tumors Advanced Solid Tumor Not Yet Recruiting
NCT06577376 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric… Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Not Yet Recruiting
NCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in… Unresectable Locally Advanced or Metastatic Solid Tumors Not Yet Recruiting
Get alerts when Shanghai Runshi Pharmaceutical Technology Co., Ltd's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free